KAILERA THERAPEUTICS INC (KLRA)
Health Care · Biotechnology · NASDAQ
Kailera Therapeutics is a clinical-stage biotechnology company advancing a diversified pipeline of GLP-1-based therapies for the treatment of obesity.
What KAILERA THERAPEUTICS INC does
Kailera Therapeutics is a clinical-stage biotechnology company focused on the development of obesity management medications. Its pipeline consists of GLP-1-based therapeutic candidates, including dual and tri-agonists, aimed at addressing weight loss and related metabolic conditions through both injectable and oral delivery methods. The company operates through a strategic license and collaboration agreement with Jiangsu Hengrui Pharmaceuticals for the development and commercialization of its product candidates outside of Greater China.
Themes: obesity / weight loss drugs, GLP-1 receptor agonists, metabolic disease, GIP receptor dual agonists, triple receptor agonists
Fundamentals
- Price$13.27 as of 2026-10-22 close
- Market cap$1.7B as of 2026-08-06 (share count; price 2026-10-22)
- P/En/a earnings data not available
- ROICn/a No figure: its 10-K tags no operating income.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta2.14 as of 2026-09-02
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
Quarterly results
Balance sheet at 2026-06-30
- Cash and equivalents$130M
- Short-term investments$786M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How KAILERA THERAPEUTICS INC looks technically
KAILERA THERAPEUTICS INC (KLRA): a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 10 trading days ago.
Trend
7
| Distance from the 200-day | not enough price history yet — needs 200 trading sessions | n/a |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $13.99 | $13.99 |
| 200-day moving average | not enough price history yet — needs 200 trading sessions | n/a |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 12 calendar days ago — the swings before that are what the structure reading is measured on | 12 sessions |
| Since the 50/200 cross | not enough price history yet — needs 200 trading sessions | n/a |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 33, with buyers in control | 33.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30) | 54.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($9.76 to $13.22) — its "stochastic" reading is 91 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 91.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 11 sessions |
Range
7
| Since a 20-day breakout | it made a new 20-day low about 10 trading days ago | 10 sessions |
|---|---|---|
| Since a 55-day breakout | it made a new 55-day low about 10 trading days ago | 10 sessions |
| All-time high | its highest closing price on record is $28.23 (set on 2026-04-20) | $28.23 |
| Given back of the 52-week move | not available for this company yet | n/a |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $9.76 (set on 2026-10-08) | $9.76 |
| Above the all-time low | it is 32.4% above its all-time low | +32.4% |
Volatility
4
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 40th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.9419 between its high and its low — about 7.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.9419 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $9.82 and $12.68 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $9.82 – $11.25 – $12.68 |
| Typical daily range (% of price) | its price moves about 7.3% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.3% |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.93× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Gap filled | a 2.1% gap down opened on 2026-09-24 has been "filled" today — price traded back through the level the gap left behind, and it took 19 sessions to close | today |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +14.84% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 7.8 percentage points (the stock gained 7.8% while the market lost 0.1%) | +7.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 33.1 percentage points (the stock lost 29.8% while the market gained 3.3%) | -33.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 58.6 percentage points (the stock lost 48.8% while the market gained 9.8%) | -58.6% |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 2 of the 7 technical signals we can compute for it are currently in a bullish state: MACD momentum is positive, a strong uptrend, with buyers in control — these describe past price behaviour, not a forecast | 2 of 7 |
|---|---|---|
| Bearish technical signals | 3 of the 7 technical signals we can compute for it are currently in a bearish state: lagging the market over 6 months, near the top of its 14-day range (overbought), trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 7 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 18% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 21.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -17.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 27% below the average price paid since 2026-04-17, so the typical buyer over that stretch is under water. That average is $17.68 — a volume-weighted average of daily closes over 120 sessions, not a true tick-by-tick VWAP. | -26.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-08-12 (its 10-Q), so the typical buyer over that stretch is under water. That average is $13.26 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -2.6% |
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 50-day moving average · in a strong, established uptrend (ADX) · Printed a doji candle · Most volatile (6%+ typical daily range) · At the top of its 14-day range (stochastic above 80) · Under water since its last earnings report (below the anchored VWAP) | Learn: adx · rsi · breakout
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.17 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$42.40 range $30.00 – $57.00; median $41.00
Analyst estimates, as of 2026-10-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for KLRA
- Consensus EPS estimate-$1.01 next reporting period, as of 2026-10-17
- Estimate change, 30 days+$0.00089 from -$1.01, on 2026-09-12, 35-day window
- Readings revised upward25% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["All product candidates are in clinical development, and there is no guarantee of regulatory approval or commercial success.","Reliance on a single strategic collaboration with Jiangsu Hengrui Pharmaceuticals for the development and supply of its product candidates.","Lack of head-to-head clinical trial data against currently approved obesity therapies."]
What changed in the latest 10-Q
AI-assisted comparison of KLRA's 10-Q filed 2026-08-12 against the prior one filed 2026-05-26.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (filed 2026-08-12) adds a July 2026 recent development stating Hengrui reported positive topline data from its Phase 3 trial of once-weekly ribupatide injection (4 mg and 2 mg) in T2D patients with inadequate glycemic control in China, with a maximum mean HbA1c reduction of 2.67% based on the efficacy estimand.
- Newer filing (filed 2026-08-12) adds an August 2026 recent development stating Hengrui reported positive topline data from its Phase 3 trial of once-weekly ribupatide injection in adults with T2D in China; mean HbA1c reductions were 2.78% (4 mg) and 2.34% (2 mg) versus 2.29% for semaglutide 1 mg, with non-inferiority met in both dose groups at Week 36 and 4 mg showing statistically significant superior HbA1c reduction versus semaglutide 1 mg.
- Newer filing (filed 2026-08-12) adds that in both ribupatide injection Phase 3 trials safety and tolerability data were consistent with other GLP-1-based treatments, with most TEAEs mild to moderate and gastrointestinal-related.
- Newer filing (filed 2026-08-12) adds a July 2026 recent development stating Hengrui reported positive topline data from two Phase 3 clinical trials of KAI-7535 (HRS-7535).
- Newer filing (filed 2026-08-12) adds Phase 3 obesity trial data for HRS-7535 180 mg: mean weight loss of up to 11.1% from baseline at Week 50, based on an ad hoc analysis under the efficacy estimand.
- Newer filing (filed 2026-08-12) adds Phase 3 obesity trial TEAE data for HRS-7535: nausea (70.3% for 120 mg and 70.0% for 180 mg vs. 16.2% placebo), vomiting (66.7% for 120 mg and 68.6% for 180 mg vs. 4.5% placebo), and diarrhea (36.9% for 120 mg and 35.9% for 180 mg vs. 15.3% placebo).
- Newer filing (filed 2026-08-12) adds Phase 3 T2D trial data for HRS-7535: lowered HbA1c by an average of 1.50% to 1.68% across all dose groups (30 mg, 60 mg, 90 mg), based on the efficacy estimand.
- Newer filing (filed 2026-08-12) adds that in both HRS-7535 Phase 3 trials most TEAEs were mild to moderate and gastrointestinal-related, and no liver safety signal was observed, consistent with prior HRS-7535 clinical trials.
- Removed:
- Older filing (filed 2026-05-26) includes a May 2026 recent development stating we and Hengrui reported positive topline data from Hengrui's Phase 3 T2D clinical trial of KAI-7535 (HRS-7535); HRS-7535 met the primary endpoint with HbA1c reduction averaging 1.40% to 1.68% across doses at Week 32, with safety and tolerability data consistent with oral GLP-1-based treatments.
- Older filing (filed 2026-05-26) includes a statement that data from Hengrui's ongoing Phase 3 clinical trial in participants living with obesity is anticipated later this year.
- Older filing (filed 2026-05-26) includes a May 2026 recent development stating we and Hengrui reported positive topline data from Hengrui's Phase 1 single ascending and multiple ascending dose trial of KAI-4729 (HRS-4729); HRS-4729 demonstrated safety and tolerability data consistent with GLP-1-based treatments, and in a secondary endpoint achieved a mean weight loss of up to 16.0% from baseline and demonstrated meaningful reductions in liver fat at Week 12.
- Reworded:
- Newer filing (filed 2026-08-12) replaces the older filing's Recent developments bullets about KAI-7535 Phase 3 T2D data and KAI-4729 Phase 1 data with new bullets about ribupatide injection Phase 3 T2D data and KAI-7535 Phase 3 obesity and T2D data.
- Newer filing (filed 2026-08-12) states 'we have funded our operations primarily with...' and ends the provided excerpt during that sentence; older filing (filed 2026-05-26) continues with '...proceeds from the sale and issuance of shares of our convertible preferred stock, the issuance of convertible promissory notes, which converted into shares of convertible preferred stock, and proceeds from the sale and issuance of our common stock as part of our initial public offering.' The older filing also includes additional subsequent financial discussion (net loss, accumulated deficit, expected future expenses) not present in the newer excerpt provided.
- Notes:
- The newer filing excerpt is truncated at the end of the Risks and uncertainties paragraph, so the comparison beyond that point (including any financial condition and results of operations detail) cannot be assessed against the older filing's additional text, which continues with financial discussion.
- The 'Our diversified GLP-1-based pipeline is summarized below:' text appears in both filings but only page numbers differ (18 in newer vs 19 in older); the pipeline graphic itself is not provided.
Risk Factors
- Reworded:
- The page number following the bulleted list changed from 29 in the filing dated 2026-05-26 to 30 in the filing dated 2026-08-12.
- Notes:
- The provided Risk Factors excerpts appear to end at the same point in both filings, mid-sentence ('...may have an adverse effect on the value'). No other differences were identified within the supplied text.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-17. The 6 days since 2026-10-17 have not been checked yet.
Cluster buying: 5 different insiders reported open-market purchases (SEC code P) of KLRA within a 30-day window between 2026-04-20 and 2026-04-20. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Most recent open-market transaction: 2026-04-20. Based on Form 4 filings read through 2026-10-17; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about KLRA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding KLRA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 14,381,043
- Reported value $316,814,378
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about KLRA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
KLRA had 8,683,381 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
KLRA had 6.70% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.62 days to cover at the same settlement.
- Reported short interest (shares) 8,683,381
- Short interest (% of shares outstanding) 6.70%
- Prior settlement (shares) 5,962,752
- Reported change 45.63%
- Days to cover (reported) 5.62
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Eli Lilly (LLY)
- Novo Nordisk (NVO)
- Viking Therapeutics (VKTX)
- Altimmune (ALT)
- Structure Therapeutics (GPCR)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare KLRA vs…
Frequently asked questions
What does KAILERA THERAPEUTICS INC (KLRA) do?
Kailera Therapeutics is a clinical-stage biotechnology company focused on the development of obesity management medications. Its pipeline consists of GLP-1-based therapeutic candidates, including dual and tri-agonists, aimed at addressing weight loss and related metabolic conditions through both injectable and oral delivery methods.
What sector is KAILERA THERAPEUTICS INC (KLRA) in?
KAILERA THERAPEUTICS INC (KLRA) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are KAILERA THERAPEUTICS INC's (KLRA) competitors?
Notable peers of KAILERA THERAPEUTICS INC (KLRA) include Eli Lilly, Novo Nordisk, Viking Therapeutics, Altimmune and Structure Therapeutics. This peer set is informational only — not financial advice.
Is KAILERA THERAPEUTICS INC (KLRA) overbought or oversold right now?
KAILERA THERAPEUTICS INC (KLRA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 55, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on KLRA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.